Clinical Trial Update: Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MEDI4736 (durvalumab) in immunological subsets of advanced colorectal cancer has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MEDI4736 (Durvalumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-06-18